Protect the unvaccinated, then offer boosters – WHO’s Ryan

DUBLIN: Getting an initial course of Covid-19 vaccines to unprotected groups all over the world should remain a top priority before offering booster shots to vulnerable groups, World Health Organisation (WHO) Emergency Director Mike Ryan said on Tuesday.

A major study on Tuesday found that two doses of Pfizer-BioNTech’s Covid-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, suggesting weaker efficacy against the new Omicron variant.

Ryan said he expected the current vaccines would provide significant protection against hospitalisation and death, but that the data coming through was very preliminary and the WHO did not have enough of it yet to make a full determination.

“People are always asking should we be going for a primary vaccination or boosters, the reality is we should be doing both,” Ryan told an online event.

“We should be focusing on getting those who are unvaccinated vaccinated as quickly as possible and then being able to give booster doses to those in vulnerable groups.”

Ryan said Omicron would most likely replace Delta as the globally dominant variant over time and that governments needed to refocus on basic protective measures such as mask wearing and make sure their hospitals were ready.

Even if Omicron turns out to be a milder disease in an individual patient, there was no doubt that the rapidly rising force of infection would generate more hospitalisations in the coming weeks just by the sheer weight of numbers, he added.

“Every single health system needs to get ready,” Ryan said. “We are going to likely to see a very large Omicron wave. We need to protect the health system, we need to protect those we love. It’s not rocket science, everyone knows how to do it.”

  • Related Posts

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad